Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies

@article{Rodgers2016SwitchmediatedAA,
  title={Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies},
  author={D. Rodgers and Magdalena Mazagova and Eric N. Hampton and Yu Cao and N. Ramadoss and Ian R. Hardy and Andrew D Schulman and Juanjuan Du and F. Wang and O. Singer and Jennifer S. Y. Ma and V. Nunez and Jiayin Shen and A. Woods and T. Wright and P. Schultz and Chan Hyuk Kim and T. Young},
  journal={Proceedings of the National Academy of Sciences},
  year={2016},
  volume={113},
  pages={E459 - E468}
}
Chimeric antigen receptor T (CAR-T) cell therapy has produced impressive results in clinical trials for B-cell malignancies. [...] Key Result Optimized switches specific for CD19 controlled the activity, tissue-homing, cytokine release, and phenotype of sCAR-T cells in a dose-titratable manner in a Nalm-6 xenograft rodent model of B-cell leukemia.Expand

Paper Mentions

Interventional Clinical Trial
This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells in all clinical trials including… Expand
ConditionsChronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), (+6 more)
InterventionCombination Product
Interventional Clinical Trial
CLBR001 + SWI019 is an combination investigational immunotherapy being evaluated as a potential treatment for patients diagnosed with B cell malignancies who are refractory or… Expand
ConditionsChronic Lymphocytic Leukemia (CLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), (+6 more)
InterventionCombination Product
New development in CAR-T cell therapy
Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
CAR-T Cells: Next Generation Cancer Therapeutics
Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer.
Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 56 REFERENCES
Challenges in T cell receptor gene therapy
Versatile strategy for controlling the specificity and activity of engineered T cells
Designing chimeric antigen receptors to effectively and safely target tumors.
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
  • M. Milone, J. Fish, +11 authors C. June
  • Biology, Medicine
  • Molecular therapy : the journal of the American Society of Gene Therapy
  • 2009
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.
Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts
An inducible caspase 9 safety switch for T-cell therapy.
...
1
2
3
4
5
...